TRQ-1201

**TRQ-1201**, also called **Deep IL-12 Primed T cells**, is an investigational adoptive T-cell therapy developed using Torque Therapeutics' Deep-Priming platform. The product consists of tumor-reactive T cells loaded ex vivo with Deep IL-12, a fusion protein comprising interleukin-12 and an anti-CD45 Fab fragment that tethers IL-12 to the T-cell surface before infusion. Surface localization is intended to concentrate IL-12 activity at tumor sites, promote local interferon-gamma production and cytotoxic T-cell function, and reduce the systemic cytokine exposure and toxicity associated with soluble IL-12. The program was investigated preclinically for solid tumors, including melanoma, and subsequently became part of Repertoire Immune Medicines following the merger of Torque Therapeutics and Cogen Immune Medicines.

Other names

antibody-tethered interleukin-12-T cellsDeep IL-12Deep IL-12 Primed T cellsDeep IL-12 tethered T cellsDeep-Primed IL-12 T cells